Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: August 27, 2009
Last updated: January 9, 2014
Last verified: August 2009

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at blood and tissue samples from patients with prostate cancer receiving androgen deprivation therapy.

Condition Intervention
Prostate Cancer
Drug: antiandrogen therapy
Drug: releasing hormone agonist therapy
Genetic: DNA analysis
Genetic: RNA analysis
Genetic: comparative genomic hybridization
Genetic: gene expression analysis
Other: laboratory biomarker analysis
Procedure: diffusion-weighted magnetic resonance imaging
Procedure: magnetic resonance spectroscopic imaging

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: A Study of Changes in the Prostate Following Androgen Deprivation to Investigate Therapy Response and Resistance in Clinical Prostate Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Identification of molecular and pathophysiological changes [ Designated as safety issue: No ]
  • Functional imaging as a non-invasive tool to measure treatment response [ Designated as safety issue: No ]
  • Development of clinical models to predict tumor response [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: September 2008
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Detailed Description:


  • To identify the molecular and pathophysiological changes which occur during the early stages of androgen deprivation (AD) and during emerging castration-resistant prostate cancer.
  • To test functional imaging as a non-invasive tool to measure treatment response and validate this using biological endpoints.
  • To develop clinical models to predict how tumors will respond to AD and identify new targets once AD fails.


  • Group A: Patients likely to receive androgen deprivation (AD) as first-line therapy undergo blood and prostate biopsy sample collection before and after treatment on days 0 and 14 or 90. Patients receive an androgen receptor inhibitor followed by maintenance with a gonadotropin-releasing hormone analogue beginning on day 0. Patients also undergo diffusion-weighted MRI, MR spectroscopic imagining, quantitative T1W mapping, and T1W perfusion sequence.
  • Group B: Patients already receiving AD undergo blood and prostate biopsy sample collection within 4 weeks of diagnosis of castration-resistant prostate cancer and before initiating any second-line therapy.

Blood and tissue samples are assessed via DNA and RNA genetic analysis, gene expression studies, and comparative genomic hybridization to identify novel markers of androgen response and resistance.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.


Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Meets 1 of the following criteria:

    • High clinical suspicion of prostate cancer, based on an abnormal digital rectal examination and PSA (> 20 ng/mL)
    • Newly diagnosed, castration-resistant prostate cancer

      • Clinical stage ≥ T2c disease
  • Significant tumor volume on initial diagnostic biopsy (> 50% of cores)
  • Likely to receive androgen deprivation therapy for prostate cancer


  • No contraindication to transrectal needle biopsy
  • No contraindication to MRI or prostate needle biopsy


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00967954

United Kingdom
Cancer Research UK at Cambridge Research Institute Recruiting
Cambridge, England, United Kingdom, CB2 0RE
Contact: Vincent Gnanapragasam, MD    44-1223-348-363      
Sponsors and Collaborators
Cancer Research UK
Principal Investigator: Vincent Gnanapragasam, MD Cancer Research UK
  More Information Identifier: NCT00967954     History of Changes
Other Study ID Numbers: CDR0000639017  CRUK-CHIRRP  EU-20920 
Study First Received: August 27, 2009
Last Updated: January 9, 2014
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
stage IIB prostate cancer
stage IIA prostate cancer
stage III prostate cancer
stage IV prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2016